447 related articles for article (PubMed ID: 10536005)
1. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons.
Morral N; O'Neal W; Rice K; Leland M; Kaplan J; Piedra PA; Zhou H; Parks RJ; Velji R; Aguilar-Córdova E; Wadsworth S; Graham FL; Kochanek S; Carey KD; Beaudet AL
Proc Natl Acad Sci U S A; 1999 Oct; 96(22):12816-21. PubMed ID: 10536005
[TBL] [Abstract][Full Text] [Related]
2. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration.
Parks R; Evelegh C; Graham F
Gene Ther; 1999 Sep; 6(9):1565-73. PubMed ID: 10490766
[TBL] [Abstract][Full Text] [Related]
3. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype.
Mack CA; Song WR; Carpenter H; Wickham TJ; Kovesdi I; Harvey BG; Magovern CJ; Isom OW; Rosengart T; Falck-Pedersen E; Hackett NR; Crystal RG; Mastrangeli A
Hum Gene Ther; 1997 Jan; 8(1):99-109. PubMed ID: 8989999
[TBL] [Abstract][Full Text] [Related]
4. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity.
Morral N; Parks RJ; Zhou H; Langston C; Schiedner G; Quinones J; Graham FL; Kochanek S; Beaudet AL
Hum Gene Ther; 1998 Dec; 9(18):2709-16. PubMed ID: 9874269
[TBL] [Abstract][Full Text] [Related]
5. Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector.
O'Neal WK; Zhou H; Morral N; Langston C; Parks RJ; Graham FL; Kochanek S; Beaudet AL
Mol Med; 2000 Mar; 6(3):179-95. PubMed ID: 10965494
[TBL] [Abstract][Full Text] [Related]
6. Persistent hepatic expression of human apo A-I after transfer with a helper-virus independent adenoviral vector.
Van Linthout S; Lusky M; Collen D; De Geest B
Gene Ther; 2002 Nov; 9(22):1520-8. PubMed ID: 12407424
[TBL] [Abstract][Full Text] [Related]
7. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors.
Pastore L; Morral N; Zhou H; Garcia R; Parks RJ; Kochanek S; Graham FL; Lee B; Beaudet AL
Hum Gene Ther; 1999 Jul; 10(11):1773-81. PubMed ID: 10446917
[TBL] [Abstract][Full Text] [Related]
8. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors.
Morral N; O'Neal W; Zhou H; Langston C; Beaudet A
Hum Gene Ther; 1997 Jul; 8(10):1275-86. PubMed ID: 9215744
[TBL] [Abstract][Full Text] [Related]
9. Advances in helper-dependent adenoviral vector research.
Segura MM; Alba R; Bosch A; Chillón M
Curr Gene Ther; 2008 Aug; 8(4):222-35. PubMed ID: 18691018
[TBL] [Abstract][Full Text] [Related]
10. Pseudo-hydrodynamic delivery of helper-dependent adenoviral vectors into non-human primates for liver-directed gene therapy.
Brunetti-Pierri N; Stapleton GE; Palmer DJ; Zuo Y; Mane VP; Finegold MJ; Beaudet AL; Leland MM; Mullins CE; Ng P
Mol Ther; 2007 Apr; 15(4):732-40. PubMed ID: 17285138
[TBL] [Abstract][Full Text] [Related]
11. [Advances in helper-dependent adenoviral vector--a review review].
Fu Y; He J; Shi C; Hong T
Wei Sheng Wu Xue Bao; 2009 Feb; 49(2):147-52. PubMed ID: 19445167
[TBL] [Abstract][Full Text] [Related]
12. Immune response to helper dependent adenoviral mediated liver gene therapy: challenges and prospects.
Seiler MP; Cerullo V; Lee B
Curr Gene Ther; 2007 Oct; 7(5):297-305. PubMed ID: 17979676
[TBL] [Abstract][Full Text] [Related]
13. The host response to adenovirus, helper-dependent adenovirus, and adeno-associated virus in mouse liver.
McCaffrey AP; Fawcett P; Nakai H; McCaffrey RL; Ehrhardt A; Pham TT; Pandey K; Xu H; Feuss S; Storm TA; Kay MA
Mol Ther; 2008 May; 16(5):931-41. PubMed ID: 18388926
[TBL] [Abstract][Full Text] [Related]
14. Improved vascular gene transfer with a helper-dependent adenoviral vector.
Wen S; Graf S; Massey PG; Dichek DA
Circulation; 2004 Sep; 110(11):1484-91. PubMed ID: 15326058
[TBL] [Abstract][Full Text] [Related]
15. Helper-dependent adenoviral vectors for gene therapy.
Palmer DJ; Ng P
Hum Gene Ther; 2005 Jan; 16(1):1-16. PubMed ID: 15703484
[TBL] [Abstract][Full Text] [Related]
16. An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus.
Maione D; Della Rocca C; Giannetti P; D'Arrigo R; Liberatoscioli L; Franlin LL; Sandig V; Ciliberto G; La Monica N; Savino R
Proc Natl Acad Sci U S A; 2001 May; 98(11):5986-91. PubMed ID: 11353820
[TBL] [Abstract][Full Text] [Related]
17. Readministration of helper-dependent adenoviral vectors to mouse airway mediated via transient immunosuppression.
Cao H; Yang T; Li XF; Wu J; Duan C; Coates AL; Hu J
Gene Ther; 2011 Feb; 18(2):173-81. PubMed ID: 20882053
[TBL] [Abstract][Full Text] [Related]
18. Helper-dependent adenovirus achieve more efficient and persistent liver transgene expression in non-human primates under immunosuppression.
Unzu C; Melero I; Hervás-Stubbs S; Sampedro A; Mancheño U; Morales-Kastresana A; Serrano-Mendioroz I; de Salamanca RE; Benito A; Fontanellas A
Gene Ther; 2015 Nov; 22(11):856-65. PubMed ID: 26125605
[TBL] [Abstract][Full Text] [Related]
19. A Cre-expressing cell line and an E1/E2a double-deleted virus for preparation of helper-dependent adenovirus vector.
Zhou H; Zhao T; Pastore L; Nageh M; Zheng W; Rao XM; Beaudet AL
Mol Ther; 2001 Apr; 3(4):613-22. PubMed ID: 11319924
[TBL] [Abstract][Full Text] [Related]
20. Helper-dependent adenoviral vectors in experimental gene therapy.
Józkowicz A; Dulak J
Acta Biochim Pol; 2005; 52(3):589-99. PubMed ID: 16082408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
